LEVAQUIN 25MG/ML SOLUTION

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

LEVOFLOXACIN

Mevcut itibaren:

JANSSEN INC

ATC kodu:

J01MA12

INN (International Adı):

LEVOFLOXACIN

Doz:

25MG

Farmasötik formu:

SOLUTION

Kompozisyon:

LEVOFLOXACIN 25MG

Uygulama yolu:

INTRAVENOUS

Paketteki üniteler:

20ML

Reçete türü:

Prescription

Terapötik alanı:

QUINOLONES

Ürün özeti:

Active ingredient group (AIG) number: 0131663002; AHFS:

Yetkilendirme durumu:

CANCELLED POST MARKET

Yetkilendirme tarihi:

2006-08-04

Ürün özellikleri

_C:\WINDOWS\TEMP\notes8F9C3E\Levaquin apm.doc _
_ Page 1 of 69 _
PRODUCT MONOGRAPH
PR
LEVAQUIN
*
levofloxacin
Tablets 250 mg, 500 mg and 750 mg
Injection 5 mg/mL in 5% dextrose
Antibacterial Agent
This Product Monograph is the exclusive property of Janssen-Ortho Inc.
It may not be copied in whole or in part without the written
permission of Janssen-Ortho Inc.
Janssen-Ortho Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen-ortho.com
Date of Revision:
July 28, 2008
SUBMISSION CONTROL NUMBER: 116931
* All trademark rights used under license
© 2008 JANSSEN-ORTHO Inc.
_C:\WINDOWS\TEMP\notes8F9C3E\Levaquin apm.doc _
_ Page 2 of 69 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND
PRECAUTIONS.........................................................................................
5
ADVERSE
REACTIONS.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
14
DOSAGE AND
ADMINISTRATION.....................................................................................
16
OVERDOSAGE
.......................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 20
STORAGE AND
STABILITY.................................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................